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Brahman Dharmarajah, MA,MRCS, Joseph Shalhoub, PhD,MRCS, andAlunH. Davies, DM, FRCS, London,
UnitedKingdom
Background: Treatment of head and neck malignancy commonly involves radiotherapy, which is associated with the
development of carotid artery stenosis. There is little evidence to guide clinicians on how to intervene in significant
postradiotherapy carotid stenosis. This systematic review collated data pertaining to perioperative outcomes of carotid
artery surgery and carotid stenting in postradiotherapy carotid stenosis to aid the clinical decision-making process.
Methods: A systematic review of the literature, adhering to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) 2009 guidelines, was performed. We screened 575 articles related to carotid artery surgery or
stenting in postradiotherapy carotid stenosis, from which 21 studies were included for quantitative analysis. The primary
outcome was stroke or death <30 days of the procedure. Secondary outcomes included cranial nerve injury, restenosis,
stroke, and death at >30 days.
Results: Nine publications recorded 211 surgical procedures in 179 patients. In symptomatic patients, the 30-day
mortality rate was 2.6% and the stroke or death rate was 2.7%. In asymptomatic patients, the 30-day mortality rate was
0% and the stroke or death rate was 1.1%. Permanent cranial nerve palsy was experienced by 0.6% of patients. Twelve
publications recorded 510 carotid artery stenting procedures in 482 patients. In symptomatic patients, the 30-day
mortality rate was 5.1%, and the stroke or death rate was 5.1%. In asymptomatic patients, the 30-day mortality rate was
1.4%, and the stroke or death rate was 2.1%. There was no statistically significant difference in 30-day stroke or death rate
between surgical revascularization and carotid artery stenting in all (odds ratio [OR], 0.54; 95% confidence interval [CI]
0.17-1.70; P .43), symptomatic (OR, 0.52; 95% CI, 0.14-1.98; P .38), or asymptomatic patients (OR, 0.55; 95% CI,
0.06-5.42; P  .99).
Conclusions: The published outcomes from high-volume centers demonstrate that surgical revascularization and stenting are
both technically feasible in postradiotherapy carotid stenosis and have similar safety profiles to nonirradiated necks. Radiation
should therefore not be considered a contraindication to surgical intervention. (J Vasc Surg 2012;56:1143-52.)
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cThe treatment of head and neck malignancy commonly
involves radiotherapy, which is associated with the devel-
opment of carotid artery stenosis.1 Whether radiotherapy
induces carotid atherosclerosis is unclear; however, there is
evidence to suggest that radiotherapy accelerates its pro-
gression.2 Radiation induces a proinflammatory reaction in
the arterial wall, increasing vascular endothelium permea-
bility and facilitating the infiltration of inflammatory cells,
contributing to plaque formation.3-5
There is a long lag time between radiation exposure and
presentation with carotid stenosis,1 and given the improved
survival of patients with head and neck cancer,6 it is increas-
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http://dx.doi.org/10.1016/j.jvs.2012.04.044ngly important to consider the management of hemody-
amically significant postradiotherapy carotid stenosis
PRCS). PRCS can lead to the same sequelae as in a
onirradiated patient, including plaque rupture, thrombo-
mbolization, and subsequent stroke. Some evidence sug-
ests that the relative risk of stroke in these patients is
igher than in nonirradiated patients with carotid stenosis.7
ntervention aims to reduce the long-term risk of stroke.
ecause patients with PRCS are excluded from most ran-
omized controlled trials,8,9 there is a limited evidence base
o guide clinical decision making.
The 2011 U.S. multi-taskforce guidelines suggest that
hen intervention is deemed necessary in PRCS, carotid ar-
ery stenting (CAS) could be performed as a reasonable alter-
ative to surgical revascularization (SR).10 However, many
roups believe that SR in a postradiotherapy neck is high risk
nd use CAS as the procedure of choice,11 despite the lack of
eriprocedural evidence to support this practice. These groups
elieve that surgery in an irradiated field can be more difficult
ue to the loss of normal tissue planes, a friable vessel wall, and
ifficulties in separating the plaque from the arterial media.12
rior radical neck dissections or tracheostomies after laryngec-
omy are thought to add to a hostile surgical field in which
ranial nerve injury is of putative higher risk.13 Concerns with
ound healing of a radiated field have also been raised.13
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diated patients to identify if technical differences affect
periprocedural safety, several large-volume centers have pub-
lished their results for both strategies.
This systematic review aims to establish the reported
safety of both SR and CAS by analyzing the 30-day stroke
or death rates in published series of patients with PRCS
undergoing carotid artery revascularization. This analysis
examines the evidence base regarding operative risk and
may aid decision making in relation to revascularization in
patients with PRCS.
METHODS
Search strategy. A systematic review adhering to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) 2009 guidelines14 was per-
formed. The databases searched included the Cochrane
Central Register of Controlled Trials, MEDLINE, and
Embase using theOvid portal. The databases were searched
on October 28, 2011, for articles published between 1947
and 2011. The search string used was carotid and radiation
or irradiation or radiotherapy and stent or stenting or
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ompared results at each stage. A third author (J.S.) arbi-
rated disagreements. After duplicates were discarded, 575
rticles were screened, of which 21 studies were included
or quantitative summation analysis (Fig).
Inclusion and exclusion criteria. Case series with at
east 10 interventions in PRCS published in any language
ere considered. Authors of cases presented in conference
roceedings were contacted for further details and were
ncluded if these were supplied. Studies were considered for
uantitative analysis according to the criteria given in Table
. Before a study was excluded from quantitative analysis,
he authors were contacted for missing information.
Primary and secondary outcomes. The primary out-
ome was stroke or death (all-cause) 30 days. Secondary
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Volume 56, Number 4 Kasivisvanathan et al 1145● Requirement of myocutaneous flap for closure of
wound, and
● Restenosis of revascularized vessel.
Analysis. A summation analysis was performed on the
included studies. The primary outcome of 30-day stroke or
death was compared between SR and CAS in all patients
and in symptomatic and asymptomatic patients. Statistical
significance was taken as P  .05 using a two-tailed Fisher
exact test to analyze differences in proportions. The analysis
was performed using Prism 5 software (GraphPad Soft-
ware, San Diego, Calif).
RESULTS
The characteristics of included studies are given in
Table II12,15-22 and Table III.11,13,16,23-31
Primary outcome. The analysis found no statistically
significant difference in the 30-day stroke or death rate
between SR and CAS in all (odds ratio [OR], 0.54; 95%
confidence interval [CI], 0.17-1.70; P  .43), symptom-
atic (OR, 0.52; 95% CI, 0.14-1.98; P  .38), or asymp-
tomatic patients (OR, 0.55; 95% CI, 0.06-5.42; P  .99).
The combined 30-day stroke, death, and stroke or death
rates across all included studies are given in Table IV.
Open SR. Nine publications recorded 211 surgical pro-
cedures in 179 patients between 1996 and 2011.12,15-22 Of
the 211 procedures, 139 (66%) were carotid endarterecto-
mies, 43 (20%) were interposition grafts, 24 (11%) were
extra-anatomic bypasses, and five (2%)were classified as other,
which consisted of one resection and anastomosis, two inter-
nal carotid ligations, and two open carotid patch angioplas-
ties. In 11 of 211 cases (5%), a myocutaneous flap was used
to close the neck wound. No studies reported dual-
antiplatelet use.
In symptomatic patients, mortality rates were reported
Table I. Inclusion and exclusion criteria
Inclusion criteria
● Prior neck radiotherapy for cancer
● Confirmed internal carotid stenosis on duplex or angiography
● Intervention of angioplasty with or without stenting or surgi-
cal revascularization
● Stated number of procedures in the patient group with break-
down of number carried out for symptomatic and asymptom-
atic carotid stenoses
● Surgical procedures, including endarterectomy, interposition
grafting or bypass grafting, or any procedure where endarter-
ectomy was attempted but a different surgical intervention
required
● Derivable primary outcomes with or without secondary out-
come(s)
Exclusion criteria
● Outcomes cannot be specifically matched to patients with
postradiotherapy carotid stenoses
● Outcomes cannot be attributed exclusively to specific surgical
or endovascular intervention
● Studies with 10 procedures
● Failure to report at least one of 30-day stroke, death, or stroke
or deathfor 116 open procedures. Three patients died 30 days, siving a 30-day mortality of 2.6%.17,18,22 All patients died
f hemorrhagic stroke. In the eight studies where type of
troke was recorded, there were three reports of any-
erritory stroke 30 days after 110 revascularizations (30-
ay stroke rate of 2.7%).17,18,22 These were all fatal hem-
rrhagic strokes, as described above. The 30-day stroke or
eath rate was three of 110 procedures (2.7%).
Ninety-five open procedures were recorded in asymp-
omatic patients, all of which reported mortality rates.
here were no deaths (30-daymortality of 0%). In the eight
tudies where stroke was recorded, one nonfatal stroke
ccurred after 87 revascularizations, giving a 30-day stroke
ate of 1.1% 16 and a 30-day stroke or death rate of 1.1%.
utcomes at 30 days by study are presented in Table V.
Carotid artery stenting. Between 2000 and 2011, 12
ublications recorded 510 carotid artery angioplasty and
tenting procedures in 482 patients.11,13,16,23-31 In the 11
tudies that reported the use of embolic protection devices,
38 of 486 procedures (70%) involved the use of embolic
rotection. Ten studies reported dual-antiplatelet therapy
efore or after the intervention.13,16,24-31
There were 249 endovascular procedures in symptom-
tic patients, all of which reported mortality rates. One
atient died of stroke 30 days, giving a 30-day mortality
f 0.4%23; however, the stroke subtype was not specified. In
he nine studies where stroke was recorded, there were nine
eports of any-territory stroke, giving a 30-day stroke rate
f 5.1%.11,16,23,24,28-30 Two patients had nondisabling
trokes,11,28 one had an ipsilateral cerebral infarct second-
ry to overinflation of the angioplasty balloon,29 and there
ere five patients with an unknown stroke type.16,23 The
0-day stroke or death rate was 5.1%.
There were 261 endovascular procedures in asymptom-
tic patients, all of which reported mortality rates. One
atient died 30 days (30-day mortality of 0.4%)23 of a
on-neurologic cause that was not specified further. In the
ine studies where stoke was recorded, there were two
trokes, giving a 30-day stroke rate of 1.4%.16,23 Details on
he type of stroke were not reported. There was a 30-day
troke or death rate of 1.4%. The 30-day outcomes by study
re given in Table VI.
econdary outcomes
Open SR. Results of open SR are reported in Table
II. All nine studies reported whether cranial nerves were
njured during the operation. There were 23 cranial nerve
njuries in 211 SRs (10.9%). However, in the eight studies
hat reported whether cranial nerve damage was transient
r permanent, there were 17 cranial nerve injuries in 175
Rs, of which only one (0.6%) was permanent.
All nine studies recorded whether wound complica-
ions of infection or delayed healing were present. Five
ound complications were reported after 211 revascular-
zations (2.4%). Seven studies recorded the occurrence of
ostoperative wound hematomas. Six hematomas were re-
orted after 169 revascularizations (3.6%).
Long-term follow-up was reported in eight of the nine
tudies, with a mean or range, or both, in months. Where
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October 20121146 Kasivisvanathan et alreported, the range of the means of follow-up was from 21
to 65 months. Five strokes and 42 deaths were reported at
30 days. The cause of death was identified in 19 patients,
with causes of death attributed to cancer in 14 (74%),
cardiac in two (11%), and stroke in one (5%; Table VIII).
Eight studies reported whether the revascularized ar-
tery restenosed during follow-up. The definition of reste-
nosis was not standardized across studies. Overall, there
were 19 reports of restenosis after 196 revascularizations
(9.7%), three of which were symptomatic (1.5%) and 12
underwent reintervention (6.1%).
Carotid artery stenting. No cranial nerve injuries
were reported in the 12 studies (Table IX). Five studies
recorded whether wound complications were present. One
complication was reported after 90 revascularizations
(1.1%). Eight studies recorded postprocedural femoral
puncture wound hematomas, with nine reported after 303
revascularizations (3.0%).
Long-term follow-up was reported in 11 of the 12
studies, with a mean or median (or both), or range in
months. The range of mean follow-up was 11 to 41
months. There were 19 strokes and 75 deaths at30 days.
The cause of death was known in 51 patients, cancer was
the cause of death in 35 (69%), cardiac causes in nine (18%),
and stroke in four (8%; Table X).
Eleven studies reported carotid restenosis during
follow-up. The definition of restenosis was not standard-
Table II. Characteristics of included studies of surgical rev
Study, year
Patients
(No.)
Age, years
Mean/median
(range) Cancer type
Year
M
Magne,15 2011 24 67 (45-82) 19 H&N
5 lymphoma
Tallarita,16 2011 27 67 17 H&N
8 breast
1 lung
1 breast
Cazaban,17 2003b 25 68 22 H&N
2 lymphoma
1 esophageal
Lesèche,18 2003 27 67 (48-84) 20 H&N
4 breast
3 lymphoma
Friedell,19 2001 10 70 (60-82) 7 H&N
2 metastatic
1 breast
Hassen-Khodja,20
2000
17 62 (49-77) 14 H&N
3 lymphoma
Kashyap,21 1999 24 62 19 H&N
3 skin
2 lymphoma
Testart,22 1997 15 44-63 15 H&N
Rockman,12 1996 10 67 (45-85) 6 H&N
3 lymphoma
1 metastatic
CEA, Carotid endarterectomy; H&N, head and neck.
aPrior neck dissection for prior head and neck cancer surgery.
bSeries updated by personal correspondence from the author.ized across studies. Overall, there were 71 reports of reste- aosis after 391 revascularizations (18.1%), of which 16
resented with symptoms (4.1%) and 24 underwent re-
ntervention (6.1%).
ISCUSSION
Little evidence is available to guide clinicians on the safety
f intervention in PRCS. Despite this, some deem SR in the
rradiated neck as being high risk. We present the periopera-
ive outcomes of CAS and SR in PRCS to address this issue.
The risks and benefits of carotid revascularization pro-
edures vary according to whether the patient presents with
ymptomatic or asymptomatic carotid stenosis; therefore, it
s essential that primary outcomes of stroke and death be
tratified by symptoms. Although this approach is lacking
rom most of the studies that report these outcomes in
RCS,32 by contacting the authors of the studies, we are
ble to present these data. One of our principal findings was
hat there was no statistically significant difference in the
0-day stroke or death rate with either technique in symp-
omatic or asymptomatic individuals.
In symptomatic patients, stroke occurred more fre-
uently after CAS (5.1%) than after SR (2.7%), which
irrors the Stenting vs Endarterectomy for Treatment of
arotid-Artery Stenosis (CREST) trial,33 which showed
3.2% perioperative stroke rate after carotid endarterec-
omy and a 5.5% perioperative stroke rate after CAS.
troke or death rates after SR (2.7%) and CAS (5.1%)
larization (SR) in postradiotherapy carotid stenosis
radiation
atment
Prior neck
dissectiona SR CEAs
Interposition
grafts
Bypass
grafts
(range) No. (%) No. No. (%) No. (%) No. (%)
-41) 6 (25) 27 1 (4) 26 (96) 0 (0)
1 11 (41) 36 29 (81) 5 (14) 2 (6)
-32) 14 (56) 34 26 (76) 0 (0) 7 (21)
-26) 13 (48) 30 20 (67) 7 (23) 3 (10)
-44) 3 (30) 11 11 (100) 0 (0) 0 (0)
-42) 10 (59) 18 12 (67) 0 (0) 6 (33)
7 10 (42) 26 20 (77) 1 (4) 1 (4)
19 9 (60) 15 10 (75) 0 (0) 5 (25)
2-31) 5 (50) 14 10 (71) 4 (29) 0 (0)ascu
s from
to tre
ean
12 (1
2
12 (3
10 (1
14 (1
10 (3
1
3-
16 (1lso appear to be comparable to those seen in CREST
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Volume 56, Number 4 Kasivisvanathan et al 1147(3.2% and 6.0%, respectively). The observed stroke or
death rates were also lower than those seen in the Stent-
protected Angioplasty vs Carotid Endarterectomy
(SPACE) trial34 (6.3% after endarterectomy and 6.8%
after stenting), the Endarterectomy vs Angioplasty in
Patients with Symptomatic Severe Carotid Stenosis
(EVA-3S) trial35 (3.9% after SR and 9.6% after CAS), and
in the International Carotid Stenting Study (ICSS)36
results (3.4% after SR and 7.4% after CAS).
For asymptomatic patients, SR and CAS both had
low 30-day stroke rates (1.1% and 1.4%, respectively),
mortality rates (0% and 0.4%, respectively), and stroke or
death rates (1.1% and 2.1%, respectively), which are
Table III. Characteristics of included studies of carotid ar
Study, year
Patients
Age, years
Mean/median
(range) Cancer typeNo.
Tallarita,16 2011 33 67 21 H&N
4 lung
4 skin
4 lymphoma
Dorresteijn,11
2010
24 68 19 H&N
3 metastasis
2 lymphoma
White,23 2010 119 67 NR
Eskandari,24 2010 49 67 (47-81) NR
Sadek,25 2009 28 72 NR
Favre,13 2008 135 67 (43-88) 116 H&N
19 otherc
Henry,26 2008 14 71 NR
Protack,27 2007 23 71 19 H&N
4 lymphoma
Skelly,28 2006 13 62 (49-87) 2 H&N
2 lymphoma
1 leukemia
8 NR
Harrod-Kim,29
2005
14 65 (52-79) 12 H&N
2 lymphoma
Ting,30 2004 16 64 16 H&N
Al-Mubarak,31
2000
14 61 (52-79) 14 H&N
EPD, Embolic protection device; H&N, head and neck; NR, not reported.
aPrior neck dissection for prior head and neck cancer surgery.
bTechnical success as defined by each study.
cParotid, thyroid, and hematologic cancer.
Table IV. Combined 30-day stroke, death, and stroke or
death rates for all included surgical revascularization and
endovascular studies, classified by symptoms
Procedures by
symptom
Stroke Death Stroke or death
No. (%) No. (%) No. (%)
Surgical
Symptomatic 3/110 (2.7) 3/116 (2.6) 3/110 (2.7)
Asymptomatic 1/87 (1.1) 0/95 (0) 1/87 (1.1)
Endovascular
Symptomatic 9/177 (5.1) 1/249 (0.4) 9/177 (5.1)
Asymptomatic 2/146 (1.4) 1/261 (0.4) 3/146 (2.1)comparable to the primary outcomes seen in CREST wstroke and stroke or death rates of 1.4% for SR vs 2.5%
or CAS). The stroke or death rates were also lower than
hose seen in the Asymptomatic Carotid Atherosclerosis
tudy (ACAS)9 and the Asymptomatic Carotid Surgery
rial (ACST).37
In summary, SR and CAS for PRCS are both techni-
ally safe and have acceptable 30-day stroke and mortality
ates for symptomatic and asymptomatic patients compared
ith carotid intervention in nonirradiated patients from
arge randomized controlled trials. Thus, on the basis of
his evidence, the approach of avoiding SR because of a
erceived high-risk procedure is not valid.
Some important lessons include the technique of SR.
arotid endarterectomy was only used in 66% of SRs.
ther techniques, such as interposition grafting or by-
ass grafting, were used when endarterectomy was
eemed difficult perioperatively. However, some sur-
eons used interposition as their primary technique, with
ood results.15 Indications for these techniques were
xtensive involvement of the distal common carotid
rtery, severe radiation arteritis rendering endarterec-
omy impossible, or an irregular or attenuated post-
ndarterectomy carotid wall.12,18,19 Reassuringly, only
% of patients undergoing surgery required a myocuta-
eous flap for wound closure, despite 45% of patients
aving had a prior neck dissection for cancer surgery. We
stenting (CAS) in postradiotherapy carotid stenosis
rs from radiation
to treatment
Prior neck
dissectiona CAS
Technical
successb EPD
Mean (range) No. (%) No. (%) No. (%)
6 24 (73) 37 92 25 (68)
13 13 (54) 24 100 NR
NR NR 119 99 106 (89)
NR 23 (47) 49 NR 49 (100)
NR 23 (82) 28 NR 28 (100)
12 NR 149 98 88 (59)
NR 5 (36) 14 100 14 (100)
NR NR 23 96 11 (48)
NR 10 (100) 17 100 13 (76)
9 (1-23) 11 (79) 17 100 0 (0)
12 (3-25) NR 18 94 4 (22)
13 13 (93) 15 100 0 (0)tery
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were not consistently reported for this group.
Although surgery led to more frequent cranial nerve
injury than stenting, only 0.6% of the reported cranial
nerve injuries were permanent. Thus, the risk of perma-
nent cranial nerve injury after surgery in the studied
patient group appears to be lower than that seen after
surgery in nonirradiated necks in large trials such as
CREST (4.7% cranial nerve palsy at 6 months). This
finding should be interpreted with caution, because one
would expect that the retrospective assessment of cranial
nerve injuries would not be as accurate as the prospective
assessment in CREST.
The frequency of cervical and puncture-site hematomas
after SR (3.6%) and CAS (3.0%) was higher than that
reported in CREST (1.5% vs 0.64%, respectively). Delayed
wound healing and infection rates were higher after SR
Table V. Rates for 30-day stroke, death, and stroke or
death after surgical revascularization (SR) in patients with
postradiotherapy carotid stenosis
Study, year
SR Stroke Death
Stroke
or death
No. No. (%) No. (%) No. (%)
Magne,15 2011
Overall 27 0 (0) 0 (0) 0 (0)
Symptomatic 9 0 (0) 0 (0) 0 (0)
Asymptomatic 18 0 (0) 0 (0) 0 (0)
Tallarita,16 2011
Overall 36 1 (2.8) 0 (0) 1 (2.8)
Symptomatic 20 0 (0) 0 (0) 0 (0)
Asymptomatic 16 1 (6.3) 0 (0) 1 (6.3)
Cazaban,17 2003
Overall 34 1 (2.9) 1 (2.9) 1 (2.9)
Symptomatic 18 1 (5.6) 1 (5.6) 1 (5.6)
Asymptomatic 16 0 (0) 0 (0) 0 (0)
Lesèche,18 2003
Overall 30 1 (3.3) 1 (3.3) 1 (3.3)
Symptomatic 17 1 (5.9) 1 (5.9) 1 (5.9)
Asymptomatic 13 0 (0) 0 (0) 0 (0)
Friedell,19 2001
Overall 11 0 (0) 0 (0) 0 (0)
Symptomatic 5 0 (0) 0 (0) 0 (0)
Asymptomatic 6 0 (0) 0 (0) 0 (0)
Hassen-Khodja,20 2000
Overall 18 0 (0) 0 (0) 0 (0)
Symptomatic 12 0 (0) 0 (0) 0 (0)
Asymptomatic 6 0 (0) 0 (0) 0 (0)
Kashyap,21 1999
Overall 26 0 (0) 0 (0) 0 (0)
Symptomatic 18 0 (0) 0 (0) 0 (0)
Asymptomatic 8 0 (0) 0 (0) 0 (0)
Testart,22 1997
Overall 15 1 (6.7) 1 (6.7) 1 (6.7)
Symptomatic 11 1 (9.1) 1 (9.1) 1 (9.1)
Asymptomatic 4 0 (0) 0 (0) 0 (0)
Rockman,12 1996
Overall 14 1 (7.1) 0 (0) 1 (7.1)
Symptomatic 6 NR 0 (0) . . .
Asymptomatic 8 NR 0 (0) . . .
NR, Not reported.than CAS (2.4% vs 1.1%, respectively), although it is diffi- iult to comment on how this compares with nonirradiated
atients because this outcome is infrequently reported in
he literature.
Owing to variation in reporting standards for reste-
osis and a lack of consistency in reporting times, it is
lso difficult to draw strong conclusions from these data.
owever, over the course of follow-up, 19 of 196 arter-
able VI. Rates of 30-day stroke, death, and stroke or
eath after carotid artery stenting (CAS) in patients with
ostradiotherapy carotid stenosis
tudy, year
CAS Stroke Death
Stroke
or death
No. No. (%) No. (%) No. (%)
allarita,16 2011
Overall 37 2 (5.4) 0 (0) 2 (5.4)
Symptomatic 19 1 (5.3) 0 (0) 1 (5.3)
Asymptomatic 18 1 (5.6) 0 (0) 1 (5.6)
orresteijn,11 2010
Overall 24 1 (4.2) 0 (0) 1 (4.2)
Symptomatic 24 1 (4.2) 0 (0) 1 (4.2)
Asymptomatic 0 . . . . . . . . .
hite,23 2010
Overall 119 5 (4.2) 2 (1.7) 6 (5.0)
Symptomatic 60 4 (6.7) 1 (1.7) 4 (6.7)
Asymptomatic 59 1 (1.7) 1 (1.7) 2 (3.4)
skandari,24 2010
Overall 49 0 (0) 0 (0) 0 (0)
Symptomatic 17 0 (0) 0 (0) 0 (0)
Asymptomatic 32 0 (0) 0 (0) 0 (0)
adek,25 2009
Overall 28 0 (0) 0 (0) 0 (0)
Symptomatic 10 0 (0) 0 (0) 0 (0)
Asymptomatic 18 0 (0) 0 (0) 0 (0)
avre,13 2008
Overall 149 2 (1.3) 0 (0) 2 (1.3)
Symptomatic 51 NR 0 (0) . . .
Asymptomatic 98 NR 0 (0) . . .
enry,26 2008
Overall 14 0 (0) 0 (0) 0 (0)
Symptomatic 9 0 (0) 0 (0) 0 (0)
Asymptomatic 5 0 (0) 0 (0) 0 (0)
rotack,27 2007
Overall 23 2 (8.7) 0 (0) 2 (8.7)
Symptomatic 11 NR 0 (0) . . .
Asymptomatic 12 NR 0 (0) . . .
kelly,28 2006
Overall 17 1 (5.9) 0 (0) 1 (5.9)
Symptomatic 14 1 (7.1) 0 (0) 1 (7.1)
Asymptomatic 3 0 (0) 0 (0) 0 (0)
arrod-Kim,29 2005
Overall 17 1 (5.9) 0 (0) 1 (5.9)
Symptomatic 10 1 (10) 0 (0) 1 (10)
Asymptomatic 7 0 (0) 0 (0) 0 (0)
ing,30 2004
Overall 18 1 (5.6) 0 (0) 1 (5.6)
Symptomatic 14 1 (7.1) 0 (0) 1 (7.1)
Asymptomatic 4 0 (0) 0 (0) 0 (0)
l-Mubarak,31 2000
Overall 15 1 (6.7) 0 (0) 1 (6.7)
Symptomatic 10 NR 0 (0) . . .
Asymptomatic 5 NR 0 (0) . . .
R, Not reported.es (9.7%) that underwent SR (range of mean follow-up,
o
w
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arteries (18.2%) that were stented (range of mean follow-
up, 11-41 months), which suggests restenosis is more
Table VII. Secondary outcomes of surgical revascularizati
Study, year
RVN
Total
CNI
Wound
complication Hematoma MC fl
No. No. (%) No. (%) No. (%) No. (%
Magne,15
2011 27 5 (18.5) 0 (0) NR 0 (0)
Tallarita,16
2011 36 6 (16.7) 3 (8.3) 2 (5.6) 3 (8.3
Cazaban,17
2003 34 4 (11.7) 0 (0) 0 (0) 0 (0)
Lesèche,18
2003 30 0 (0) 0 (0) 2 (6.7) 0 (0)
Friedell,19
2001 11 0 (0) 0 (0) 0 (0) 3 (27.
Hassen-
Khodja,20
2000 18 2 (11.1) 0 (0) 1 (5.6) 0 (0)
Kashyap,21
1999 26 6 (23.1) 2 (7.7) 1 (3.8) 4 (15.
Testart,22
1997 15 0 (0) 0 (0) NR 0 (0)
Rockman,12
1996 14 0 (0) 0 (0) 0 (0) 1 (7.1
CNI, Cranial nerve injury; MC, myocutaneous flap required for closure of w
aRestenosis as defined by criteria within each study.
Table VIII. Causes of death 30 days after surgical revas
Study, year
Patients
No.
Deaths
No.
Cancer rela
No. (%)
Magne,15 2011 24 11 . . .
Tallarita,16 2011 27 3 3 (100)
Cazaban,17 2003 25 12 8 (67)
Lesèche,18 2003 27 12 . . .
Hassen-Khodja,20 2000 17 4 3 (75)
Table IX. Secondary outcomes of carotid artery stenting
Study, year
RVN
Wound
complications Hematoma
Fol
M
No. No. (%) No. (%)
Tallarita,16 2011 33 0 (0) 0 (0)
Dorresteijn,11 2010 24 NR NR
White,23 2010 119 NR NR
Eskandari,24 2010 49 NR 2 (4.1)
Sadek,25 2009 28 NR 1 (3.6)
Favre,13 2008 135 NR 4 (3.0)
Henry,26 2008 14 0 (0) 0 (0)
Protack,27 2007 23 NR 1 (4.3)
Skelly,28 2006 13 0 (0) 0 (0)
Harrod-Kim,29 2005 14 0 (0) 1 (7.1)
Ting,30 2004 16 1 (6.3) NR
Al-Mubarak,31 2000 14 NR NR
NI, Not investigated; NR, not reported; RVN, revascularizations.
aRestenosis as defined by criteria within each study.common after endovascular intervention. tLimited conclusions can be drawn from the long-term
utcomes of stroke and death because the studies have a
ide range of follow-up times and there is a lack of consis-
Follow-up,
months
30-day
stroke
30-day
death Restenosisa Reintervention
ean (range) No. (%) No. (%) No. (%) No. (%)
28 (6-120) 1 (3.7) 11 (40.7) 5 (18.5) 5 (18.5)
65 (1-132) 1 (2.8) 3 (8.3) 4 (11.1) 2 (5.6)
60 (3-170) 1 (2.9) 12 (35.3) 1 (2.9) 1 (2.9)
40 (3-99) 1 (3.3) 12 (40) 3 (10) 2 (6.7)
37 (12-60) 0 (0) 0 (0) 1 (9.1) 0 (0)
52 (12-108) 0 (0) 4 (22) 2 (11.1) 1 (5.6)
21 (1-156) 0 (0) NR 3 (11.5) 1 (3.8)
NR . . . . . . . . . . . .
12-60 1 (7.1) 0 (0) 0 (0) 0 (0)
; NR, not reported; RVN, revascularizations.
ization
Cause of death
Stroke Cardiac related Other medical Unknown
No. (%) No. (%) No. (%) No. (%)
. . . . . . . . . 11 (100)
0 (0) 0 (0) 0 (0) 0 (0)
1 (8) 1 (8) 2 (17) 0 (0)
. . . . . . . . . 12 (100)
0 (0) 1 (25) 0 (0) 0 (0)
p, months
median
nge)
30-day
stroke
30-day
death Restenosisa Reintervention
No. (%) No. (%) No. (%) No. (%)
-83) 3 (9.1) 11 (33.3) 8 (24.2) 5 (15.2)
-132) 3 (12.5) 7 (29.2) 7 (29.2) 1 (4.2)
I NI NI NI NI
-87) 4 (8.2) 16 (32.7) 5 (10.2) 3 (6.1)
-45) NR NR 1 (3.6) 0 (0)
-95) 5 (3.7) 30 (22.2) 27 (20) 5 (3.7)
4 0 (0) 2 (14.3) 0 (0) 0 (0)
4 2 (8.7) 2 (8.7) 10 (43.5) 3 (13.0)
-29) 0 (0) 0 (0) 6 (46.2) 3 (23.1)
-78) 1 (7.1) 1 (7.1) 4 (28.6) 3 (21.4)
-55) 1 (6.3) 3 (18.8) 3 (18.8) 1 (6.3)
8 0 (0) 3 (21.4) 0 (0) 0 (0)on
ap
) M
)
3)
3)
)
oundcular
tedlow-u
ean/
(ra
41 (1
39 (4
N
18 (0
11 (1
30 (3
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1
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28 (5
30 (5
1ency in reporting of these outcomes at specific time peri-
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atic status. However, cancer-related causes were the most
common causes of death at 30 days. In patients under-
going SR (range of mean follow-up, 21-65 months), where
the cause was known, 74% of deaths were due to cancer,
and in patients undergoing CAS (range of mean follow-up,
11-41 months), 69% of deaths were due to cancer. This
contrasts with large prospective trials of carotid interven-
tion in nonirradiated carotid stenosis, where the most com-
mon cause of death is vascular disease.8,9
This raises the question of whether it is appropriate
to intervene in patients with such a high risk of death due
to their underlying cancer, given that a patient needs to
survive for long enough to derive the long-term benefit
from a stroke prevention intervention. It is therefore
essential that an assessment of life expectancy in conjunc-
tion with an oncologist take place for each patient to
consider whether the patient’s prognosis merits carotid
intervention.38
This is particularly relevant for asymptomatic disease,
which represents most of the interventions performed in
the United States.39 Some evidence does question the
benefit of SR over best medical therapy in nonirradiated
asymptomatic patients.40 To truly establish the benefit of
intervention in PRCS, one must compare the outcomes
after intervention with best medical therapy. No such
trials for PRCS exist, and thus, we are limited to com-
paring the data presented here with safety cutoffs from
large trials in patients without radiation to make in-
formed conclusions.
The study has several limitations because of the rarity of
the condition. The published studies consist largely of
nonrandomized single-center case series. Some were pro-
spective and others retrospective, and some had involve-
ment of a neurologist, although others did not. It is,
however, unlikely that sufficient numbers of irradiated pa-
tients will ever be available for a randomized controlled
trial. Further, the reported results are from high-volume
centers experienced in carotid surgery or stenting, which
see a sufficient volume of patients to enable case series of
PRCS to be reported. These centers are likely to have better
Table X. Causes of death 30 days after carotid artery ste
Study
Patients
No.
Deaths
No.
Cancer related
No. (%)
Tallarita,16 2011 33 11 10 (91)
Dorresteijn,11 2010 24 7 1 (14)
Eskandari,24 2010 49 16 . . .
Favre,13 2008 135 30 20 (67)
Henry,26 2008 14 2 . . .
Protack,27 2007 23 2 . . .
Harrod-Kim,29 2005 14 1 1 (100)
Ting,30 2004 16 3 1 (33)
Al-Mubarak,31 2000 14 3 2 (67)results than the average practitioner. WWe also recognize the risk of publication bias for the
rimary end point and reporting bias in, for example,
ranial nerve injury, where a neurologist was not always the
ssessor. There is the possibility that fewer unfavorable
esults would have been published for SR compared with
AS, which, as a more recently introduced and evaluated
echnique, may suffer from less publication bias. In addi-
ion, the studies span a long time period, as far back as
996. Medical therapy has improved in this time, and the
ontribution of this to the results is difficult to take into
ccount.
Finally, different techniques of SR may result in differ-
nt outcomes, although a more detailed breakdown is not
ossible with the currently available data. However, on the
asis of their collective outcomes, these all appear to have
n adequate safety profile.
To address these limitations, prospective long-term
egistry data are required. The rarity of the PRCS will
ecessitate national or international multicenter data col-
ection to generate the required numbers to confirm revas-
ularization in irradiated patients is being performed safely.
ONCLUSIONS
The implications of this review are that SR and CAS are
oth technically feasible in patients with PRCS and are no
ess safe than in nonirradiated patients. Thus, on the basis of
hese data, experienced clinicians should not avoid one
echnique because of fears of worse periprocedural out-
omes. Before considering any intervention, particularly in
symptomatic patients, the multidisciplinary team should
arefully consider the patient’s oncologic prognosis. Future
ork should focus on the collection of registry data on
rradiated patients and on an understanding of the annual
troke rates in irradiated patients treated with contempo-
ary radiotherapy protocols and primary preventative med-
cal therapy.
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